CS
IMDX

Credit Suisse’s Insight Molecular Diagnostics IMDX Stock Holding History

Credit Suisse’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2
Closed – – 4201
2022
Q2 		$0 Buy
+2
New +$45 ﹤0.01% 4189
2021
Q1 		– Sell
-939
Closed -$45K – 4478
2020
Q4 		$45K Buy
+939
New +$34.5K ﹤0.01% 4262

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return

Credit Suisse's IMDX Position: Q3 2022 in Review

Credit Suisse sold out of Insight Molecular Diagnostics (IMDX) in Q3 2022, closing a stake of 2 shares.

Credit Suisse first reported a position in IMDX in Q4 2020 and held it in 2 quarters. The position peaked at $45K in Q4 2020. 65 funds tracked by Wall St. Rank hold IMDX as of Q3 2022.

  • Credit Suisse reported no remaining Insight Molecular Diagnostics position as of Q3 2022 after selling out during the quarter.
  • Credit Suisse sold 2 Insight Molecular Diagnostics shares in Q3 2022.
  • Credit Suisse first reported a position in Insight Molecular Diagnostics in Q4 2020 and held it in 2 quarters.
  • Credit Suisse's Insight Molecular Diagnostics position peaked at $45K in Q4 2020.
  • 65 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.